Loading…
Loading…
EQUITY / NASDAQ · XNCM
Context Therapeutics Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗0.3004 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 0.3004 USD · Volume 1,192,885
680 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Cash and cash equivalents | 42,990,371 USD | — | — |
| Net income | -14,558,426 USD | -8,827,510 USD | — |
| Operating profit | -14,967,491 USD | -9,758,362 USD | — |
| Total assets | 46,134,154 USD | — | — |
| Total equity | 38,172,051 USD | 82,544,322 USD | -53.76% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 42,990,371 USD | — | — | 65,995,228 USD | 65,995,228 USD | 76,938,183 USD | — | — |
| Net incomeIncome statement | -14,558,426 USD | -23,238,998 USD | -8,680,572 USD | — | -36,123,615 USD | -9,693,237 USD | -23,098,008 USD | -8,827,510 USD |
| Operating profitIncome statement | -14,967,491 USD | -24,311,290 USD | — | — | -39,702,631 USD | -10,610,480 USD | -25,897,985 USD | -9,758,362 USD |
| Total assetsBalance sheet | 46,134,154 USD | — | — | 68,493,768 USD | 68,493,768 USD | 79,231,160 USD | — | — |
| Total equityBalance sheet | 38,172,051 USD | — | 52,202,375 USD | 60,473,727 USD | 60,473,727 USD | 73,174,166 USD | — | 82,544,322 USD |
| Total liabilitiesBalance sheet | 7,962,103 USD | — | — | 8,020,041 USD | 8,020,041 USD | 6,056,994 USD | — | — |
| Capital expendituresCash flow statement | — | 55,746 USD | — | — | 33,948 USD | — | 33,948 USD | — |
| Financing cash flowCash flow statement | — | 0 USD | — | — | -15,268 USD | — | -15,268 USD | — |
| Investing cash flowCash flow statement | — | -4,555,746 USD | — | — | -2,033,948 USD | — | -33,948 USD | — |
| Operating cash flowCash flow statement | — | -18,449,111 USD | — | — | -26,385,380 USD | — | -17,442,425 USD | — |
| Report source | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 03/23/2026 | Open report ↗ Published: 11/05/2025 | Open report ↗ Published: 11/05/2025 | Open report ↗ Published: 08/05/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.